Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia

Benjamin J. Dorfman, Joohi Jimenez-Shahed

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Introduction: Tardive dyskinesia (TD) is a hyperkinetic movement disorder that arises as a complication of exposure to dopamine receptor blocking agents. Vesicular monoamine transporter type 2 (VMAT2) inhibitors reduce dyskinesia by decreasing transport of monoamines, including dopamine, into presynaptic vesicles, leaving unpackaged dopamine to be metabolized by monoamine oxidase. Deutetrabenazine was adapted from an earlier VMAT2 inhibitor, tetrabenazine, by substituting three deuterium isotopes in place of three hydrogen isotopes at the site of metabolic degradation to improve upon the pharmacokinetics of the parent compound. Areas covered: The authors reviewed the pivotal trials examining the safety and efficacy of deutetrabenazine, as well as long-term data from an open-label extension. Also reviewed were posters and oral presentations, as well as information from the product label and the United States Food and Drug Administration. Expert opinion: Deutetrabenazine is effective at decreasing dyskinesia in TD, but drug selection and cost-effectiveness between existing VMAT2 inhibitors are evolving areas of study. Other areas of investigation include novel anti-dyskinetic agents and use of deep brain stimulation.

Original languageEnglish
Pages (from-to)9-20
Number of pages12
JournalExpert Review of Neurotherapeutics
Issue number1
StatePublished - 2021


  • Abnormal involuntary movements
  • SD-809
  • VMAT2 inhibitor
  • abnormal involuntary movement scale
  • deutetrabenazine
  • dopamine receptor blocking agent
  • tardive dyskinesia
  • tardive syndromes
  • vesicular monoamine transporter type 2


Dive into the research topics of 'Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia'. Together they form a unique fingerprint.

Cite this